Nanocarriers’ entry into the cell: relevance to drug delivery

By H. Hillaireau, P. Couvreur. Cellular and Molecular Life Sciences, 2009

1,492 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

The journey of a drug-carrier in the body: an anatomo-physiological perspective. (2012, background): “The surface properties of the CDCs also influence interactions with macrophages in a complex manner [132].”
To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. (2010, background): “We distinguish “nanospheres” in which the drug is dispersed throughout the particles and “nanocapsules” in which the drug is entrapped in a cavity surrounded by a polymer membrane [6].”
Potential toxicity of superparamagnetic iron oxide nanoparticles (SPION) (2010, background): “Possible mechanisms of uptake include passive diffusion, receptor-mediated endocytosis, clathrin-mediated endocytosis, caveolin-mediated internalisation, and other calthrin and caveolin-independent endocytosis (105, 106).”
PLGA-based nanoparticles: an overview of biomedical applications. (2012, background): “Nanoparticles also allow a targeted administration to specific organs or cells or controlled drug delivery [1,2].”
Insight into Cellular Uptake and Intracellular Trafficking of Nanoparticles (2018, background): “Phagocytosis and pinocytosis can be distinguished by the size of their endocytotic vesicles; the former encompass uptake of large particles by large vesicles with the size of 250 nm, and the latter encompass uptake of fluids through small vesicles with the size in the range of a few nanometres to hu”